The Ebola virus causes a hemorrhagic fever that progresses rapidly and that has high mortality rates. An experimental vaccine involving a combination of DNA immunization and boosting with adenoviral vectors (ADV) against the most lethal subtype (Zaire) of Ebola virus exists. However, this vaccine requires more than 6 months to achieve complete immunization, rendering it impotent in limiting an acute epidemic. In the August 7
Sullivan et al. vaccinated cynomolgus macaques with an ADV vector encoding the Ebola glycoprotein (GP) and nucleoprotein (NP) vectors. They observed that after immunization with ADV–GP/NP, the antibody response to immunization was more rapidly induced than after DNA priming and ADV boosting, but it ...